NASDAQ: MENSJyong Biotech Ltd Stock
$2.22+0.17 (+8.29%)
Updated Jul 2, 2026
MENS Price
$2.22
Fair Value Price
-$0.24
Market Cap
$168.78M
52 Week Low
$1.43
52 Week High
$67.00
P/E
-37x
P/B
-6.78x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$4.67M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
-1.83
Operating Cash Flow
-$3M
Beta
2.27
Next Earnings
Aug 13, 2026
Ex-Dividend
N/A
Next Dividend
N/A
MENS Overview
Jyong Biotech Ltd. is a Taiwanese biotechnology enterprise dedicated to the research, development, and market introduction of botanical therapeutics, specifically aimed at addressing diseases of the urinary system. Its operations are orchestrated through various subsidiary entities, including Health Ever Bio-Tech and Genvace. The company is actively advancing a robust pipeline of drug candidates, which notably features MCS-2, currently undergoing Phase III trials for benign prostatic hyperplasia (BPH); PCP, which is in Phase II development for prostate cancer; and IC, presently in pre-clinical stages.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine MENS's potential to beat the market
- MENS doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
MENS
RankedUnranked of 463
RankedUnranked of 463
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $10.29 | A | |
| $243.47 | A | |
| $15.61 | A |
Be the first to know about important MENS news, forecast changes, insider trades & much more!
MENS News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how MENS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
MENS ($2.22) is overvalued by 1,033.07% relative to our estimate of its Fair Value price of -$0.24 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
MENS ($2.22) is not significantly undervalued (1,033.07%) relative to our estimate of its Fair Value price of -$0.24 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
MENS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more MENS due diligence checks available for Premium users.
Valuation
MENS fair value
Fair Value of MENS stock based on Discounted Cash Flow (DCF)
Price
$2.22
Fair Value
-$0.24
Undervalued by
1,033.07%
MENS ($2.22) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
MENS ($2.22) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
MENS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
MENS price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-37x
Industry
17.59x
Market
8.55x
MENS price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-6.78x
Industry
5.6x
MENS's financial health
Profit margin
Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
MENS's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$20.8M
Liabilities
$45.7M
Debt to equity
-1.83
MENS's short-term liabilities ($34.81M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
MENS's short-term assets ($15.54M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
MENS's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
MENS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
N/A
Investing
N/A
Financing
N/A
MENS's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
MENS vs Biotech Stocks
Jyong Biotech Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.